Resultados de búsqueda - Jacqulyne Robichaux

  • Mostrando 1 - 14 Resultados de 14
Limitar resultados
  1. 1
    Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial

    Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial por Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Don L. Gibbons, Frank V. Fossella, Vincent K. Lam, Anisha B. Patel, Marcelo V. Negrão, Xiuning Le, Frank E. Mott, Jianjun Zhang, Lei Feng, George R. Blumenschein, Anne S. Tsao, John V. Heymach

    Publicado 2021
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

    Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype por Monique B. Nilsson, Jacqulyne Robichaux, Matthew H. Herynk, Tina Cascone, Xiuning Le, Yasir Y. Elamin, Sonia Patel, Fahao Zhang, Li Xu, Limei Hu, Lixia Diao, Li Shen, Junqin He, Xiaoxing Yu, Petros Nikolinakos, Pierre Saintigny, Bingliang Fang, Luc Girard, Jing Wang, John D. Minna, Ignacio I. Wistuba, John V. Heymach

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer

    Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer por Roy S. Herbst, Thomas John, Christian Grohé, Jonathan W. Goldman, Terufumi Kato, К. К. Лактионов, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine, Myung‐Ju Ahn, Dariusz M. Kowalski, M. Pérol, Virote Sriuranpong, Mustafa Özgüroğlu, Preetida J. Bhetariya, Aleksandra Markovets, Yuri Rukazenkov, Caitlin Muldoon, Jacqulyne Robichaux, Ryan J. Hartmaier, Masahiro Tsuboi, Yi‐Long Wu

    Publicado 2025
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

    OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) por John V. Heymach, Marcelo V. Negrão, Jacqulyne Robichaux, B. Carter, Ami Patel, Mehmet Altan, Don L. Gibbons, Frank V. Fossella, George R. Simon, Vincent K. Lam, George R. Blumenschein, Anne S. Tsao, Jonathan M. Kurie, Frank E. Mott, David W. Jenkins, David H. Mack, Lei Feng, Brent Roeck, Zane Yang, V. Papadimitrakopoulou, Yasir Y. Elamin

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

    A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components por Monique B. Nilsson, Huiying Sun, Jacqulyne Robichaux, Matthias Pfeifer, Ultan McDermott, Jon Travers, Lixia Diao, Yuanxin Xi, Pan Tong, Li Shen, Mia Hofstad, Masanori Kawakami, Xiuning Le, Xi Liu, You-Hong Fan, Alissa Poteete, Limei Hu, Marcelo V. Negrão, Hai T. Tran, Ethan Dmitrovsky, David H. Peng, Don L. Gibbons, Jing Wang, John V. Heymach

    Publicado 2020
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

    Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer por Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada‐Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R. Brahmer, Mehmet Altan, Charles Lu, Vassiliki A. Papadimitrakopoulou, Katerina Politi, Robert C. Doebele, Kwok‐Kin Wong, John V. Heymach

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC

    Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC por Xiuning Le, Sonam Puri, Marcelo V. Negrão, Monique B. Nilsson, Jacqulyne Robichaux, Theresa A. Boyle, J. Kevin Hicks, Katherine L. Lovinger, Emily Roarty, Waree Rinsurongkawong, Ming Tang, Huiying Sun, Yasir Y. Elamin, Lara Lacerda, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, William N. William, Bonnie S. Glisson, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, Jhanelle E. Gray, John V. Heymach

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

    CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance por Monique B. Nilsson, Yan Yang, Simon Heeke, Sonia Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y. Elamin, César A. Moran, Yukie Kashima, Thiruvengadam Arumugam, Xiaoxing Yu, Xiaoyang Ren, Lixia Diao, Li Shen, Qi Wang, Minying Zhang, Jacqulyne Robichaux, Chunhua Shi, Allyson N. Pfeil, Hai T. Tran, Don L. Gibbons, Jason Bock, Jing Wang, John D. Minna, Susumu Kobayashi, Xiuning Le, John V. Heymach

    Publicado 2023
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

    Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations por Marcelo V. Negrão, Victoria M. Raymond, Richard B. Lanman, Jacqulyne Robichaux, Junqin He, Monique B. Nilsson, Patrick Kwok‐Shing Ng, Bianca Amador, Emily Roarty, Rebecca J. Nagy, Kimberly C. Banks, Viola W. Zhu, Chun Fai Ng, Young Kwang Chae, Jeffrey Clarke, Jeffrey A. Crawford, Funda Meric‐Bernstam, Sai‐Hong Ignatius Ou, David R. Gandara, John V. Heymach, Trever G. Bivona, Caroline E. McCoach

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

    Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity por Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Hai T. Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrão, Monique B. Nilsson, Anisha B. Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhang, Lauren A. Byers, Charles Lu, Tina Cascone, Lei Feng, Rajyalakshmi Luthra, F. Anthony San Lucas, Geeta S. Mantha, Mark Routbort, George R. Blumenschein, Anne S. Tsao, John V. Heymach

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

    Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity por Jacqulyne Robichaux, Yasir Y. Elamin, R.S.K. Vijayan, Monique B. Nilsson, Lemei Hu, Junqin He, Fahao Zhang, Marlese A. Pisegna, Alissa Poteete, Huiying Sun, Shuai Li, Ting Chen, Han Han, Marcelo V. Negrão, Jordi Rodón, Lixia Diao, Jing Wang, Xiuning Le, Funda Meric‐Bernstam, Mark Routbort, Brent Roeck, Zane Yang, Victoria M. Raymond, Richard B. Lanman, Garrett M. Frampton, Vincent A. Miller, Alexa B. Schrock, Lee A. Albacker, Kwok‐Kin Wong, Jason B. Cross, John V. Heymach

    Publicado 2019
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Structure-based classification predicts drug response in EGFR-mutant NSCLC

    Structure-based classification predicts drug response in EGFR-mutant NSCLC por Jacqulyne Robichaux, Xiuning Le, R.S.K. Vijayan, J. Kevin Hicks, Simon Heeke, Yasir Y. Elamin, Heather Lin, Hibiki Udagawa, Ferdinandos Skoulidis, Hai T. Tran, Susan Varghese, Junqin He, Fahao Zhang, Monique B. Nilsson, Lemei Hu, Alissa Poteete, Waree Rinsurongkawong, Xiaoshan Zhang, Chenghui Ren, Xiaoke Liu, Lingzhi Hong, Jianjun Zhang, Lixia Diao, Russell W. Madison, Alexa B. Schrock, Jennifer Saam, Victoria M. Raymond, Bingliang Fang, Jing Wang, Min Jin Ha, Jason B. Cross, Jhanelle E. Gray, John V. Heymach

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

    Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer por Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin, Xiuning Le, Michael E. Goldberg, Karthikeyan Murugesan, Chang‐Jiun Wu, Jianhua Zhang, David S Barreto, Jacqulyne Robichaux, Alexandre Reuben, Tina Cascone, Carl M. Gay, K. G. Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Don L. Gibbons, Bonnie S. Glisson, Gaurav Singal, Vincent A. Miller, Brian M. Alexander, Garrett M. Frampton, Lee A. Albacker, David S. Shames, Jianjun Zhang, John V. Heymach

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target por Xiuning Le, Marcelo V. Negrão, Alexandre Reuben, Lorenzo Federico, Lixia Diao, Daniel J. McGrail, Monique B. Nilsson, Jacqulyne Robichaux, Irene Guijarro Munoz, Sonia Patel, Yasir Y. Elamin, You-Hong Fan, Won-Chul Lee, Edwin R. Parra, Luisa M. Solis Soto, Runzhe Chen, Jun Li, Tatiana V. Karpinets, Roohussaba Khairullah, Humam Kadara, Carmen Behrens, Boris Sepesi, Ruiping Wang, Mingrui Zhu, Linghua Wang, Ara A. Vaporciyan, Jack A. Roth, Stephen G. Swisher, Cara Haymaker, Jianhua Zhang, Jing Wang, Kwok‐Kin Wong, Lauren A. Byers, Chantale Bernatchez, Jianjun Zhang, Ignacio I. Wistuba, Don L. Gibbons, Esra A. Akbay, John V. Heymach

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: